DIRS.INFO The most relevant business & tech news

☆ Twice-yearly shot proves successful at preventing HIV infection among women, trial data shows
▼ + stars: | 2024-07-24 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +9 min

CNN —Two shots a year of a drug currently used to treat HIV infections were dramatically effective at preventing infections in a study among young women and adolescent girls in Africa. The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and published Wednesday in the New England Journal of Medicine. The twice-a-year injections of lenacapavir could add another option at preventing HIV infections to the toolbox. The latest Phase 3 findings are part of Gilead’s PURPOSE program, which comprises five HIV prevention trials around the world. “While Gilead awaits additional phase 3 clinical trial data and the potential regulatory filings for HIV prevention administered twice-yearly, it is too early to state the price of lenacapavir for PrEP (prevention).

Persons: drugmaker Gilead, ” Linda, Gail Bekker, Desmond Tutu, “, ”, Dan Barouch, hasn’t, Gilead, Dr, Jason Zucker, Barouch, ” Zucker, Lenacapavir, Gilead spokeperson, lenacapavir, Sanjay Gupta, Daniel O’Day Organizations: CNN, New England, of Medicine, International AIDS, PrEP, University of Cape, International AIDS Society, Center, Virology, Vaccine, Beth Israel Deaconess Medical, United, lenacapavir, Columbia University Irving Medical Center, ”, US Food and Drug Administration, AIDS, CNN Health, People’s Medicines Alliance, Medicines Locations: Africa, Munich, University of Cape Town, South Africa, Uganda, Argentina, Brazil, Mexico, Peru, Thailand, United States, United Kingdom, Germany, Gilead, Europe

☆ PrEPVacc: HIV vaccine trial that could be ‘the last roll of the dice’ this decade is underway
▼ + stars: | 2023-08-28 | by ( Tom Page | Thomas Page | ) edition.cnn.com time to read: +24 min

CNN —A novel trial that has been described as “the last roll of the dice” for a generation of HIV vaccines has entered its latter stages. Nearly 40 years since HIV was identified as the cause of AIDS, and 36 years since the first HIV vaccine trial, the medical community still does not have a working vaccine. But that is not necessarily why they were chosen to participate, said Eugene Ruzagira, PrEPVacc trial director. Evaluating the combination of a trial HIV vaccine and PrEP is a first, say organizers. “I did my very first HIV vaccine trial in 1991,” recalled Weber.

Persons: PrEPVacc, ”, Jonathan Weber, Frank, Helena Herholdt, Eugene Ruzagira, Ruzagira, “, Weber, ” Ruzagira, “ We’ve, Mark Runnacles, Edward Jenner, Louis Pasteur, Galileo, Win McNamee, Humphry Davy, JEAN, SEBASTIEN EVRARD, Haydn West, Joe Raedle, ANNE, CHRISTINE POUJOULAT, Alexander Fleming, Fleming, wasn't, Louise Joy Brown, Sandy Huffaker, Daniel Acker, James Watson, Francis Crick, Rosalind Franklin, Watson, Crick, Raphael GAILLARDE, Sean Gallup, Wilhelm Conrad Röntgen, Thomas Edison's, INDRANIL MUKHERJEE, Descovy, Luwano Geofrey, Dr, Luke Dray, Geofrey, Nishanta Singh, Sharon Lewin, Lewin, “ it’s, it’s, ” Lewin, ” Geofrey Organizations: CNN, Imperial College Academic Health Science Centre, PrEPVacc, Medical Research, Uganda Virus Research Institute, European Union, Smithsonian National Museum of, Cleveland Clinic, Volvo, Bayer, U.S . Food, Drug Administration, Getty, Keystone, — Farmers, Food and Drug Administration, FDA, Bloomberg, PANTHAKY, PrEP, US Centers for Disease Control, Independent, The University of Melbourne, International AIDS Society, Muhimbili University of Health, Allied Sciences, Dar Locations: Entebbe, Uganda, Thailand, London, Mbeya, Tanzania, South Africa, Ugandan, Durban, Masaka, Salam, African, Africa, China, FPG, AFP, United States, America, U.S, Peoria , Illinois, Europe, “, Dar es Salaam, Rwanda

☆ An early-stage HIV vaccine is showing positive results. If it works, it would be first successful HIV vaccine after almost 40 years of research.
▼ + stars: | 2022-12-01 | by ( Sarah Braner | ) www.businessinsider.com time to read: +4 min

An early trial for an experimental HIV vaccine candidate has shown promising results. 97% of recipients in a phase 1 study showed immune system activity in response to the vaccine. Researchers have been trying to create an HIV vaccine for nearly 40 yearsHIV is notoriously difficult to vaccinate against. By evolving and changing quickly, it can avoid the immune system by making itself harder to recognize. "That's sort of a whole new way of thinking about how to make a vaccine," Schief said.

☆ Pentagon and Army sued over decades-old policy barring recruits with HIV
▼ + stars: | 2022-11-11 | by ( Zachary Schermele | ) www.nbcnews.com time to read: +4 min

After a successful effort earlier this year to ease longstanding restrictions on service members living with HIV, LGBTQ rights advocates are now pushing for more change. They want to end the U.S. military’s decades-old policy of barring people with HIV from enlisting. Isaiah Wilkins, 23, tested positive for HIV while trying to join the Army Reserves. Lambda LegalThe lawsuit describes the ban on HIV-positive recruits as “incompatible” with modern medical advancements. Before the court ruling, U.S. military policy was to place restrictions on service members if they were diagnosed with HIV after they had successfully enlisted.

Search resuls for: "International AIDS Society"

4 mentions found